# Study Comparing Cyclosporin Dose Reduction With Cyclosporin Elimination in Kidney Transplant Recipients Taking Sirolimus

> **NCT00248313** · PHASE3 · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 470 (—)

## Conditions studied

- Kidney Disease

## Interventions

- **DRUG:** Rapamune®

## Key facts

- **NCT ID:** NCT00248313
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-07
- **Primary completion:** —
- **Final completion:** 2007-10
- **Target enrollment:** 470 (—)
- **Last updated:** 2010-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00248313

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00248313, "Study Comparing Cyclosporin Dose Reduction With Cyclosporin Elimination in Kidney Transplant Recipients Taking Sirolimus". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00248313. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*